<DOC>
	<DOCNO>NCT00591123</DOCNO>
	<brief_summary>In study , Erlotinib 5-Fluorouracil ( 5-FU ) , Leucovorin Oxaliplatin ( regimen know also FOLFOX-6 ) chemotherapy study drug . The main purpose study test safety effectiveness combination chemotherapy drug see affect cancer . Another purpose study examine sample blood tumor . This research do well understand subject respond treatment . Specifically , researcher look way gene proteins respond drug like use study .</brief_summary>
	<brief_title>Study Erlotinib Chemotherapy Unresectable Metastatic Cancer Esophagus Gastric Cardia</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Metastatic unresectable adenocarcinoma upper gastrointestinal tract measure least one dimension accord RECIST criterion CT MRI 2 . Gastric adenocarcinoma may include primary tumor arises within 5 cm anatomic gastroesophageal junction ( distal esophagus ) gastric cardia indicate either endoscope imaging . 3 . Previously untreated chemotherapeutic agent unresectable metastatic disease . 4 . Adjuvant chemotherapy and/or radiotherapy allow long oxaliplatin use past 12 month . 5 . ECOG performance status 0 1 6 . Age &gt; 18 year old . 7 . Life expectancy great 6 month . 8 . Peripheral neuropathy : must &lt; grade 1 9 . Absolute neutrophil count &gt; 1,500/mm3 10 . Hemoglobin &gt; 9.0 g/dl 11 . Platelet count &gt; 100,000/mm3 12 . Hepatic Function : 1 . Total Bilirubin &lt; = 1.5 x ULN 2 . AST ALT must &lt; = 3.0 x ULN ( &lt; = 5.0 x ULN liver metastasis ) . 13 . Creatinine clearance &gt; 60 ml/min calculate Cockcroft Gault formula . ( Ccr = ( ( 140Age ) X Wt ( kg ) ) / ( 72 X SCr ( mg/100ml ) male ) . ( Ccr = ( ( 140Age ) X Wt ( kg ) ) / ( 72 X SCr ( mg/100ml ) x 0.85 female ) 14 . Women childbearing potential must negative pregnancy test urine serum test . 15 . Men woman childbearing potential must willing consent use effective contraception treatment least 4 month last treatment . 16 . Patients must sign IRB approve informed consent 17 . Patients must ability comply study followup procedure . 1 . Patients know hypersensitivity component oxaliplatin , leucovorin , 5fluorouracil ( fluoropyrimidines ) erlotinib . 2 . Women breastfeed pregnant . 3 . Presence &gt; Grade 2 neuropathy 4 . Patients prior malignancy nonmelanoma skin cancer cervical carcinoma situ within past five year 5 . Current prior history central nervous system brain metastases 6 . Any medical condition , , opinion investigator , would preclude subject participate study . 7 . Patients receive chemotherapy , surgery radiation therapy within 30 day prior first dose . 8 . INR great 3.5 patient warfarin 9 . Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Esophagus</keyword>
	<keyword>Gastric Cardia</keyword>
</DOC>